📊 IRTC Key Takeaways
Is IRTC a Good Investment? Thesis Analysis
iRhythm demonstrates strong revenue growth (+26.2% YoY) and excellent gross margins (70.6%), but profitability remains deeply challenged with operating and net losses persisting. The company generates positive free cash flow ($34.5M) with a strong balance sheet, but must demonstrate a clear path to operating profitability before warranting aggressive positioning.
Why Buy IRTC? Key Strengths
- Strong revenue growth of 26.2% YoY indicating market demand for cardiac monitoring solutions
- Excellent gross margin of 70.6% demonstrating pricing power and efficient production
- Solid liquidity position with $236M cash, 4.63x current ratio, and 0.23x debt-to-equity providing financial flexibility
- Positive free cash flow of $34.5M despite operating losses showing underlying cash generation capability
- Healthy balance sheet with stockholders' equity of $152.7M providing cushion for operations
IRTC Investment Risks to Consider
- Persistent operating losses of -$57.4M and negative net margin of -6.0% with no clear path to profitability despite revenue growth
- Operating cash flow of $80.9M heavily dependent on working capital management; sustainability questioned given ongoing losses
- Negative interest coverage ratio of -5.8x indicating inability to cover debt service from operating earnings
- High insider activity with 31 Form 4 filings in 90 days warrants monitoring for potential confidence issues
- Negative ROE of -29.2% and ROA of -4.4% demonstrating value destruction for shareholders despite asset base
Key Metrics to Watch
- Operating income trend - critical to achieve positive operating income within 2-3 quarters
- Operating margin progression - target minimum 5-10% margin to validate business model sustainability
- Free cash flow sustainability - ensure positive FCF persists as company scales operations
- Gross margin stability - monitor for compression that would indicate pricing pressure or manufacturing inefficiencies
- Revenue growth deceleration - watch if growth rate moderates below 20% YoY signaling market saturation
IRTC Financial Metrics
💡 AI Analyst Insight
The relatively thin 4.6% FCF margin may limit capital allocation flexibility. Strong liquidity with a 4.63x current ratio provides a solid financial cushion.
IRTC Profitability Ratios
IRTC vs Healthcare Sector
How iRhythm Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IRTC Overvalued or Undervalued?
Based on fundamental analysis, iRhythm Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IRTC Balance Sheet & Liquidity
IRTC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: iRhythm Holdings, Inc.'s revenue has grown significantly by 131% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.04 indicates the company is currently unprofitable.
IRTC Growth Metrics (YoY)
IRTC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $147.5M | -$5.2M | $-0.16 |
| Q2 2025 | $148.0M | -$14.2M | $-0.44 |
| Q1 2025 | $131.9M | -$30.7M | $-0.97 |
| Q3 2024 | $124.6M | -$18.5M | $-0.89 |
| Q2 2024 | $124.1M | -$18.5M | $-0.61 |
| Q1 2024 | $111.4M | -$39.1M | $-1.29 |
| Q3 2023 | $103.9M | -$18.5M | $-0.71 |
| Q2 2023 | $102.1M | -$18.5M | $-0.61 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IRTC Capital Allocation
IRTC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for iRhythm Holdings, Inc. (CIK: 0001388658)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRTC
What is the AI rating for IRTC?
iRhythm Holdings, Inc. (IRTC) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRTC's key strengths?
Claude: Strong revenue growth of 26.2% YoY indicating market demand for cardiac monitoring solutions. Excellent gross margin of 70.6% demonstrating pricing power and efficient production.
What are the risks of investing in IRTC?
Claude: Persistent operating losses of -$57.4M and negative net margin of -6.0% with no clear path to profitability despite revenue growth. Operating cash flow of $80.9M heavily dependent on working capital management; sustainability questioned given ongoing losses.
What is IRTC's revenue and growth?
iRhythm Holdings, Inc. reported revenue of $747.1M.
Does IRTC pay dividends?
iRhythm Holdings, Inc. does not currently pay dividends.
Where can I find IRTC SEC filings?
Official SEC filings for iRhythm Holdings, Inc. (CIK: 0001388658) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRTC's EPS?
iRhythm Holdings, Inc. has a diluted EPS of $-1.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRTC a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, iRhythm Holdings, Inc. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRTC stock overvalued or undervalued?
Valuation metrics for IRTC: ROE of -29.2% (sector avg: 15%), net margin of -6.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRTC stock in 2026?
Our dual AI analysis gives iRhythm Holdings, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IRTC's free cash flow?
iRhythm Holdings, Inc.'s operating cash flow is $80.9M, with capital expenditures of $46.3M. FCF margin is 4.6%.
How does IRTC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6.0% (avg: 12%), ROE -29.2% (avg: 15%), current ratio 4.63 (avg: 2).